Defining the maximum tolerated dose: An update

Journal of Clinical Pharmacology

Volumn 40, Issue 11, 2000, Pages 1183-1204

  Cutler, Neal R ^a   Sramek, John J ^a   Greenblatt, David J ^b   Chaikin, Philip ^c   Collins, Jerry ^d  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; 3 PHENYL 1 [(1,2,3,4 TETRAHYDRO 5,6 METHYLENEDIOXY 1 NAPHTHYL)METHYL]PYRROLIDINE; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; DOCETAXEL; FANANSERIN; FIBRINOGEN RECEPTOR ANTAGONIST; ILOPERIDONE; LESOPITRON; MILAMELINE; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANXIETY NEUROSIS; CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG RESEARCH; DRUG TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM ALLOWABLE CONCENTRATION; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SCHIZOPHRENIA;

EID: 0033753271     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)